Merck Sharp & Dohme Corp. have identified nicotinic α7 receptor positive allosteric modulators reported to be useful for the treatment of Alzheimer’s and Parkinson’s diseases, and schizophrenia.
Zeno Management Inc. researchers have prepared and tested azole compounds described as transcriptional enhancer factor (TEAD) inhibitors potentially useful for the treatment of autoimmune diseases, inflammation and cancer.
Benzimidazole carboxylic acids acting as glucagon-like peptide 1 receptor (GLP-1R) agonists have been reported in a Terns Pharmaceuticals Inc. patent as potentially useful for the treatment of diabetes, obesity and liver diseases.
Research at Incyte Corp. has led to the development of hetero-tricyclic compounds acting as GTPase KRAS (mutant) inhibitors and thus reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Lomond Therapeutics Inc. has prepared and tested compounds having N-arylpyrimidin-2-amine derivatives and acting as protein kinase inhibitors, particularly mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1). As such, they are reported to be useful for the treatment of autoimmune diseases, sepsis, neurodegeneration, male infertility, vascular and inflammatory disorders, cancer and viral infections.
Clevudine derivatives and its phosphoramidates have been detailed in an Emory University patent as potentially useful for the treatment of hepatitis B virus (HBV) infection.
Long Island University and Mount Sinai School of Medicine have jointly developed intermediate conductance KCa3.1 (IKCa1) channel blockers reported to be useful for the treatment of renal disorders.
RSS